Prospects of using pancragen for correction of metabolic disorders in elderly people.
Korkushko. O V OV; Khavinson. V Kh VKh; Shatilo. V B VB; Antonyk-Sheglova. I A IA; Bondarenko. E V EV
Key Findings
- Elderly diabetics had a 70% reduction in nocturnal melatonin compared to healthy age‑matched controls.
- Pancragen administration significantly lowered fasting glucose, improved oral glucose tolerance test results, and reduced plasma insulin and insulin‑resistance index (HOMA‑IR).
- No metabolic improvements were observed in a comparable group that did not receive pancragen.
Practical Outcomes
- Pancragen shows promise as an experimental tool to improve insulin sensitivity in older adults, especially those with low melatonin. However, the study provides limited details on dosage, safety, and long‑term effects, so biohackers should treat it as a pilot finding and await more robust data before incorporating it into regular protocols.
Summary
In older people with type‑2 diabetes, nighttime melatonin was much lower than in healthy peers. Giving the tetrapeptide pancragen lowered fasting blood sugar, improved glucose tolerance, and reduced insulin and insulin‑resistance markers, while people who didn’t get the peptide saw no change. The authors suggest that fixing melatonin‑related problems with pancragen might help older adults combat insulin resistance.
Abstract
We examined two groups of older persons: 30 healthy and 33 patients with type 2 diabetes mellitius. Nocturnal melatonin production was significantly reduced by 70% in patients with DM2 compared to healthy individuals of the corresponding age. In patients with DM2, pancragen significantly decreased glucose level on an empty stomach and in standard glucose tolerance test and reduced plasma concentrations of insulin and insulin resistance index. In patients receiving no pancragen, no changes in carbohydrate metabolism indices were observed. Thus, disturbances in the melatonin-producing function of the pineal gland in elderly individuals contribute to the development of insulin resistance. Administration of the tetrapeptide pancragen is a promising approach to the correction of insulin resistance in elderly individuals.
Study Information
pubmed
2011
2011-08-17T00:00:00.000Z
10.1007/s10517-011-1354-4
5
13